FAMILY OF SMALL MOLECULE COMPOUNDS THAT INHIBIT BOTH HIV REVERSE TRANSCRIPTASE AND INTEGRASE

Human immunodeficiency virus (HIV) is believed to be the etiological agent of acquired immunodeficiency syndrome (AIDS). Chemotherapeutic strategies for treating AIDS or HIV infection have traditionally targeted critical enzymes in the viral life cycle. Treatments with reverse transcriptase inhibitors and protease inhibitors have been successful for some patients. However, others do not respond and viral strains are developing which may make the use of these drugs ineffective. This suggests that new treatment methods are necessary.

Scientists at UCSF have developed a family of novel compounds with anti-viral properties against retroviruses, particularly as inhibitors of HIV reverse transcriptase and/or HIV integrase. These novel compounds should be advantageous due to their multiple sites of attack and their effectiveness in drug resistant strains of HIV. Moreover, these new drugs should be adaptable for use in combination therapies against HIV.

If you would like to receive further information about this technology and potential licensing opportunities, please contact:

Joel B. Kirschbaum, Ph.D.
Director & Senior Technology Portfolio Manager
(415) 353-4462 phone
(415) 348-1579 fax
Joel Kirschbaum, Ph.D.

Reference: OTM Case #SF97-134